Home
Project
Recruiting sites
Partners
Impact
Resources
Contact
News

27th Annual ESGCT Congress

LERU: how innovative medicines could reach the patients faster

October 9, 2019

Article about gene therapy in de Volkskrant

January 21, 2020

27th Annual ESGCT Congress

Some members of the Recomb consortium are present at the 27th Annual ESGCT congress in Barcelona. We wish all participants a successful meeting. Read more about the very exciting programme of the congress

Anita Ordas

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About us

The RECOMB consortium brings together a large number of clinical and research professionals from 16 European and 1 Israeli institutes with expertise in the management of primary immunodeficiencies, such as SCID.

Our mission

The ultimate aim of RECOMB is to create a treatment for the most common type of SCID, RAG1-SCID by performing phase 1 and phase 2 clinical trials using autologous haematopoietic stem cell‒based gene therapy.

Useful links

Learn more about Primary immunodeficiencies
Learn more about SCID
Learn more about Gene Therapy

This project has received funding from the European Union’s Horizon 2020 research and
innovation programme under grant agreement n° 755170’

© 2025 RECOMB. All Rights Reserved. Muffin group